Presbyopia

Spectacle independence is not the main factor that determines patients’ lens selections, according to study investigators.

The approval will allow LensGen to move forward with the IDE pivotal trial with the ultimate goal of seeking premarket approval in the United States.

This model can restore visual function and provide good intermediate and near vision in both photopic and mesopic conditions.

The VIVID study focuses on three novel topical ophthalmic formulations under investigation for the treatment of presbyopia

Lens combines diffractive multifocal and extended depth-of-focus properties.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia.

Demographics show high demand for solutions beyond eyeglasses.